Handelsblatt model portfolio: Fresenius shares remain in the portfolio

The editorial depot: Ulf Sommer, Handelsblatt

The development of the Fresenius share. The healthcare company has not yet benefited from the corona pandemic. In several business areas, sales even shrank in the second quarter because hospitals in Europe and the USA postponed planned operations and the beds were therefore underutilized.

For the year as a whole, CEO Stephan Sturm expects sales growth adjusted for currency effects of three to six percent as well as consolidated earnings of between an increase of one percent and a decrease of four percent.

Read on now

Get access to this and every other article in the

Web and in our app for 4 weeks free of charge.

Further

Read on now

Get access to this and every other article in the

Web and in our app for 4 weeks free of charge.

Further

.

See Also:  Hecatomb at D'Ieteren Auto: the transformation plan will ultimately cost 123 redundancies

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.